Eden vs Midi Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Eden
Best for mainstream telehealth GLP-1 accessStarting at $189/mo
Midi Health
Best for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss productStarting at $128/mo
Side-by-Side Comparison
| Feature | Eden | Midi Health |
|---|---|---|
| Overall Score | ✓7.2/10 | 7.0/10 |
| Starting Price | $189/mo | ✓$128/mo |
| Editorial Rating | ✓3.6 ★ /5 | 3.5 ★ /5 |
| Features | 3 features | ✓4 features |
| States Available | ✓50 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Eden
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Midi Health
Pros
- ✓Nationwide availability in all 50 states (verified on the public homepage)
- ✓Accepts commercial insurance — differentiator vs most cash-pay-only GLP-1 telehealth
- ✓Menopause + metabolic health specialty framing — useful for women in the demographic where GLP-1 efficacy and weight regulation overlap most
- ✓Compounded semaglutide pricing starts at $127.90/mo for uninsured patients per the public pricing/insurance page
Cons
- ✗Does NOT accept Medicare, Medicaid, or Medi-Cal — eliminates roughly 40% of the insured US adult population
- ✗GLP-1 prescribing is clinician-discretionary inside a broader menopause care plan, NOT a guaranteed offering at intake — readers signing up purely for GLP-1 access may not get it
- ✗Menopause-focused — not the right fit for men or younger women whose primary need is weight loss
Our Verdict
Eden edges out Midi Health with a higher overall score of 7.2/10 and is particularly strong for mainstream telehealth GLP-1 access. Midi Health remains a solid alternative, especially if you're looking for women in menopause / perimenopause with commercial insurance who want GLP-1 prescribing as part of a broader hormone + metabolic care plan, not as a standalone weight-loss product.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.